Verizon Communications Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Verizon Communications Inc trades at $43.74 (market cap $181.64B), while State Street SPDR S&P Biotech ETF trades at $154.5. The key difference: Verizon Communications Inc pays a 6.51% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Verizon Communications Inc nearer its low. Which is the better fit depends on your goals.
| VZ | XBI | |
|---|---|---|
Market Cap | $181.64B | — |
Volume | 22,584,735 | — |
Sector | Media | Broad Market / Factor |
52-Week High | $51.38 | $164.28 |
52-Week Low | $38.40 | $85.16 |
Enterprise Value | $369.14B | — |
Dividend Yield | 6.51% | — |
Signals from Pluang's Aura AI — not financial advice
Verizon (VZ) trades at $43.78, up 0.44% today, with a bearish technical signal but strong fundamentals including a P/E of 10.61 and consistent earnings beats. Recent news highlights a restructuring involving 3,000 job cuts and the sale of 274 stores to franchisees, aimed at boosting efficiency ahead of Q2 2026 earnings. Cash flow improved in 2025 with net cash flow of $14.9 billion, supporting its 6.5% dividend yield.
Outlook: Attractive for income investors due to stable cash flows and high dividend, but faces risks from 5G competition and margin pressure. Analyst consensus price target is $47.83, suggesting upside potential if execution improves. Key risks include debt levels and industry discounts threatening profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →